Corvia Medical, Inc.

Corvia Medical, Inc. develops innovative medical devices focused on treating symptomatic heart failure, particularly for patients with heart failure with preserved or mildly reduced ejection fraction, enhancing patient quality of life. Founded in 2009 and based in the US, Corvia Medical, Inc. specializes in medical devices for heart failure treatment.

The company has not undergone any significant pivots in strategy or operations since its inception. The CEO, George Fazio, leads the company as it focuses solely on its core mission. In June 2025, Corvia Medical, Inc. raised USD 55 million in venture funding from returning investors Third Rock Ventures, General Catalyst Partners, Accelmed, and Lumira Ventures.

Other unspecified investors also participated in the round. Corvia Medical, Inc. specializes in medical devices designed to treat symptomatic heart failure, particularly focusing on patients with heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF). Their core product, the Corvia Atrial Shunt System (IASD®), is engineered to alleviate heart failure-related symptoms and improve overall quality of life for individuals with elevated left atrial pressures who continue to experience symptoms despite conventional medical therapies.

The IASD® functions by creating a controlled atrial shunt that reduces left atrial pressure, thereby mitigating the symptoms associated with heart failure. Corvia Medical targets healthcare providers, hospitals, and specialized heart clinics, primarily within the United States and select international markets, aiming to service patients who are in need of innovative treatment options for heart failure management. Corvia Medical's revenue generation is primarily associated with the sales of its flagship product, the Corvia Atrial Shunt System (IASD®). The company engages in direct transactions with healthcare institutions and medical professionals, facilitating the acquisition of their investigational device for use in eligible patients.

These transactions typically occur through established partnerships with hospitals and clinics, allowing for streamlined distribution and access to their products. Revenue is generated as healthcare providers procure the IASD® system to incorporate it into their treatment modalities for heart failure, ensuring that patients receive appropriate care. Additionally, the company may explore agreements with distributors in various geographical markets to enhance opportunities for revenue generation. The company will use the June 2025 funding for the completion of RESPONDER-HF trial.